Sionna Therapeutics, Inc.
SIONSionna Therapeutics, Inc. in brief
Sionna Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Waltham, Massachusetts, USA. Its market value was $183 M on 29 October 2026, which makes it the 16,585th largest listed company in the world and the 3,209th largest in the USA on this site. It employs about 59 people and Michael Cloonan is its chief executive. Its shares trade under the symbol SION (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Sionna Therapeutics, Inc.
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator protein to deliver clinically meaningful benefit to people with CF. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which lead to insufficient CFTR function. While advances in the discovery and development of CFTR modulators have significantly improved the lives of people with CF, at least two-thirds of patients on the current standard of care do not have normal CFTR function, defined as sweat chloride levels below 30 mmol/L. Patients with reduced CFTR function can experience debilitating multi-system complications that lead to significantly impaired quality of life and shorter life expectancy. Our goal is to deliver differentiated medicines for people with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide binding domain 1. Despite having long been identified as a critical component for proper CFTR function, NBD1 has been considered “undruggable,” and none of the currently approved CF therapies directly stabilizes NBD1. Leveraging more than a decade of our co-founders’ research on NBD1, we are advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, the most common CFTR mutation, which occurs in the NBD1 domain. Approximately 90% of people with CF carry at least one copy of the F508del genetic mutation.
From the company's annual report filed with the US SEC: read the report
Sionna Therapeutics, Inc. timeline
- 2024
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2025
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 7 February 2025; shares registered for exchange trading on 4 February 2025.
Events of Sionna Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #2,885 (Aug 2026) · #3,213 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 0.6×
- Free cash flow yield
- -36.5%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -24.5%
- Liabilities / assets
- 5.9%
- Profit per employee
- $-1.3 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-89M | $-75M | — |
| Dec 2024 | — | — | $-71M | $-62M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-66M | $0M | $-67M | $-1.88 | — |
| Dec 2024 | $-53M | $0M | $-53M | $-15.99 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-32M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 10, 202610-QQuarterly report · period to Sep 2026
- Nov 10, 20268-KCurrent reportResults of operations
- Sep 14, 20268-KCurrent reportRestructuring costs · Directors or officers changed · Other events
- Aug 10, 20268-KCurrent reportOther events
- Aug 6, 202610-QQuarterly report · period to Jun 2026
- Aug 6, 20268-KCurrent reportResults of operations
- Jun 18, 20268-KCurrent reportShareholder vote
- May 12, 202610-QQuarterly report · period to Mar 2026
- May 12, 20268-KCurrent reportResults of operations
- Apr 27, 2026DEF 14AProxy statement
- Mar 2, 202610-KAnnual report · period to Dec 2025
- Mar 2, 20268-KCurrent reportResults of operations
Official filings of Sionna Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-89 M
- Net income
- $-75 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $326 M
- Total liabilities
- $19 M
- Total equity
- $307 M
As of December-2025
Top 100 institutional investors in Sionna Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | TPG GP A, LLC | 6,494,962 | 0 (0.00%) | 14.36% | $34 M | Nov 16, 2026 |
| 2 | Ra Capital Management, L.P. | 6,456,234 | -3,448,811 (-34.82%) | 14.27% | $34 M | Nov 16, 2026 |
| 3 | Viking Global Investors LP | 3,195,181 | 0 (0.00%) | 7.06% | $17 M | Nov 16, 2026 |
| 4 | Atlas Venture Life Science Advisors, LLC | 2,995,602 | 0 (0.00%) | 6.62% | $16 M | Nov 10, 2026 |
| 5 | Goldman Sachs Group Inc | 2,720,289 | +2,331,479 (+599.64%) | 6.01% | $14 M | Nov 16, 2026 |
| 6 | BlackRock, Inc. | 2,675,216 | +1,200,447 (+81.40%) | 5.91% | $14 M | Nov 13, 2026 |
| 7 | Enavate Sciences GP, LLC | 2,478,030 | 0 (0.00%) | 5.48% | $13 M | Nov 16, 2026 |
| 8 | Orbimed Advisors LLC | 2,469,959 | -85,918 (-3.36%) | 5.46% | $13 M | Nov 16, 2026 |
| 9 | Jennison Associates LLC | 1,992,812 | +820,679 (+70.02%) | 4.41% | $10 M | Nov 16, 2026 |
| 10 | Millennium Management LLC | 1,462,690 | +1,185,957 (+428.56%) | 3.23% | $8 M | Nov 16, 2026 |
| 11 | Aberdeen Group plc | 1,343,137 | +1,058,999 (+372.71%) | 2.97% | $7 M | Nov 10, 2026 |
| 12 | Vanguard Capital Management LLC | 1,189,396 | +57,395 (+5.07%) | 2.63% | $6 M | Nov 13, 2026 |
| 13 | Y-Intercept (Hong Kong) Ltd | 1,056,885 | New | 2.34% | $6 M | Oct 16, 2026 |
| 14 | Acadian Asset Management LLC | 553,956 | New | 1.22% | $3 M | Nov 9, 2026 |
| 15 | Geode Capital Management, LLC | 539,509 | +82,364 (+18.02%) | 1.19% | $3 M | Nov 6, 2026 |
| 16 | Walleye Capital LLC | 453,319 | +355,972 (+365.67%) | 1.00% | $2 M | Nov 13, 2026 |
| 17 | Marshall Wace, LLP | 444,016 | +431,417 (+3424.22%) | 0.98% | $2 M | Nov 13, 2026 |
| 18 | Voleon Capital Management LP | 429,584 | New | 0.95% | $2 M | Nov 16, 2026 |
| 19 | Boxer Capital Management, LLC | 391,723 | New | 0.87% | $2 M | Nov 16, 2026 |
| 20 | Bank Of America Corp /de/ | 378,110 | +289,202 (+325.28%) | 0.84% | $2 M | Nov 16, 2026 |
| 21 | State Street Corp | 377,179 | -644,355 (-63.08%) | 0.83% | $2 M | Nov 12, 2026 |
| 22 | AQR Capital Management LLC | 326,393 | New | 0.72% | $2 M | Nov 16, 2026 |
| 23 | Morgan Stanley | 303,883 | +152,836 (+101.18%) | 0.67% | $2 M | Nov 13, 2026 |
| 24 | Vanguard Portfolio Management LLC | 299,620 | +76,671 (+34.39%) | 0.66% | $2 M | Nov 13, 2026 |
| 25 | Point72 Asset Management, L.P. | 263,401 | +214,073 (+433.98%) | 0.58% | $1 M | Nov 16, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | BNP Paribas Financial Markets | 262,736 | +230,933 (+726.14%) | 0.58% | $1 M | Nov 12, 2026 |
| 27 | HSBC Holdings PLC | 260,602 | New | 0.58% | $1 M | Nov 16, 2026 |
| 28 | Trexquant Investment LP | 233,675 | +209,865 (+881.42%) | 0.52% | $1 M | Nov 16, 2026 |
| 29 | Susquehanna Portfolio Strategies, LLC | 212,620 | +194,586 (+1079.00%) | 0.47% | $1 M | Nov 16, 2026 |
| 30 | Schonfeld Strategic Advisors LLC | 170,797 | New | 0.38% | $1 M | Nov 16, 2026 |
| 31 | Northern Trust Corp | 168,814 | +14,338 (+9.28%) | 0.37% | $1 M | Nov 16, 2026 |
| 32 | Jump Financial, LLC | 161,330 | +150,857 (+1440.44%) | 0.36% | $1 M | Nov 13, 2026 |
| 33 | Vanguard Fiduciary Trust Co | 148,865 | +27,423 (+22.58%) | 0.33% | $1 M | Nov 13, 2026 |
| 34 | Charles Schwab Investment Management Inc | 146,047 | +16,294 (+12.56%) | 0.32% | $1 M | Nov 16, 2026 |
| 35 | Citigroup Inc | 133,964 | +23,801 (+21.61%) | 0.30% | $1 M | Nov 4, 2026 |
| 36 | Tang Capital Management LLC | 125,000 | New | 0.28% | $1 M | Nov 16, 2026 |
| 37 | Quantinno Capital Management LP | 113,117 | New | 0.25% | $1 M | Nov 13, 2026 |
| 38 | Jane Street Group, LLC | 105,394 | New | 0.23% | $1 M | Nov 12, 2026 |
| 39 | Rock Springs Capital Management LP | 99,429 | 0 (0.00%) | 0.22% | $1 M | Nov 16, 2026 |
| 40 | Algert Global LLC | 91,770 | New | 0.20% | $0 M | Nov 17, 2026 |
| 41 | Gsa Capital Partners LLP | 88,680 | New | 0.20% | $0 M | Nov 16, 2026 |
| 42 | Caitong International Asset Management Co., Ltd | 88,580 | +88,549 (+285641.94%) | 0.20% | $0 M | Oct 29, 2026 |
| 43 | Rhenman & Partners Asset Management AB | 87,500 | -9,600 (-9.89%) | 0.19% | $0 M | Nov 12, 2026 |
| 44 | Driehaus Capital Management LLC | 87,272 | -298,175 (-77.36%) | 0.19% | $0 M | Nov 16, 2026 |
| 45 | Ikarian Capital, LLC | 85,300 | New | 0.19% | $0 M | Nov 16, 2026 |
| 46 | BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 72,518 | New | 0.16% | $0 M | Nov 13, 2026 |
| 47 | Axq Capital, LP | 71,794 | +67,197 (+1461.76%) | 0.16% | $0 M | Nov 12, 2026 |
| 48 | Jain Global LLC | 70,918 | +66,138 (+1383.64%) | 0.16% | $0 M | Nov 16, 2026 |
| 49 | Opaleye Management Inc. | 70,000 | New | 0.15% | $0 M | Nov 16, 2026 |
| 50 | UBS Group AG | 65,916 | -50,290 (-43.28%) | 0.15% | $0 M | Nov 10, 2026 |
| 51 | ExodusPoint Capital Management, LP | 65,520 | New | 0.14% | $0 M | Nov 16, 2026 |
| 52 | Alps Advisors Inc | 59,475 | +13,950 (+30.64%) | 0.13% | $0 M | Nov 3, 2026 |
| 53 | Nuveen, LLC | 53,199 | +11,940 (+28.94%) | 0.12% | $0 M | Nov 10, 2026 |
| 54 | Dimensional Fund Advisors LP | 51,954 | New | 0.11% | $0 M | Nov 4, 2026 |
| 55 | Bank of New York Mellon Corp | 46,271 | +4,685 (+11.27%) | 0.10% | $0 M | Nov 5, 2026 |
| 56 | Barclays PLC | 46,005 | +39,510 (+608.31%) | 0.10% | $0 M | Nov 6, 2026 |
| 57 | Creative Planning | 43,381 | New | 0.10% | $0 M | Nov 2, 2026 |
| 58 | Prelude Capital Management, LLC | 32,361 | New | 0.07% | $0 M | Nov 16, 2026 |
| 59 | Canada Pension Plan Investment Board | 32,100 | New | 0.07% | $0 M | Nov 16, 2026 |
| 60 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 28,533 | +17,911 (+168.62%) | 0.06% | $0 M | Nov 16, 2026 |
| 61 | Atom Investors LP | 27,637 | New | 0.06% | $0 M | Nov 16, 2026 |
| 62 | XTX Topco Ltd | 27,552 | -10,544 (-27.68%) | 0.06% | $0 M | Nov 16, 2026 |
| 63 | Swiss National Bank | 27,000 | 0 (0.00%) | 0.06% | $0 M | Nov 12, 2026 |
| 64 | Tower Research Capital LLC (TRC) | 26,094 | +24,815 (+1940.19%) | 0.06% | $0 M | Nov 16, 2026 |
| 65 | Virtu Financial LLC | 25,448 | New | 0.06% | $0 M | Nov 17, 2026 |
| 66 | Boothbay Fund Management, LLC | 24,860 | New | 0.06% | $0 M | Nov 16, 2026 |
| 67 | Alliancebernstein L.P. | 24,250 | -1,200 (-4.72%) | 0.05% | $0 M | Nov 16, 2026 |
| 68 | Rhumbline Advisers | 21,852 | -457 (-2.05%) | 0.05% | $0 M | Nov 10, 2026 |
| 69 | FMR LLC | 21,176 | -257,116 (-92.39%) | 0.05% | $0 M | Nov 10, 2026 |
| 70 | State of Alaska, Department of Revenue | 20,000 | New | 0.04% | $0 M | Oct 15, 2026 |
| 71 | Price T Rowe Associates Inc /MD/ | 19,585 | -458,431 (-95.90%) | 0.04% | $0 M | Nov 16, 2026 |
| 72 | Jpmorgan Chase & Co | 18,756 | -1,471,752 (-98.74%) | 0.04% | $0 M | Nov 12, 2026 |
| 73 | Wells Fargo & Company/mn | 16,841 | +20 (+0.12%) | 0.04% | $0 M | Nov 16, 2026 |
| 74 | Deutsche Bank AG\ | 16,734 | -36,619 (-68.64%) | 0.04% | $0 M | Nov 6, 2026 |
| 75 | Citadel Advisors LLC | 16,188 | -1,131,448 (-98.59%) | 0.04% | $0 M | Nov 16, 2026 |
| 76 | Russell Investments Group, Ltd. | 15,702 | -26,556 (-62.84%) | 0.03% | $0 M | Nov 6, 2026 |
| 77 | Engineers Gate Manager LP | 15,147 | -456 (-2.92%) | 0.03% | $0 M | Nov 16, 2026 |
| 78 | California State Teachers Retirement System | 14,852 | 0 (0.00%) | 0.03% | $0 M | Nov 13, 2026 |
| 79 | Two Sigma Investments, LP | 14,300 | New | 0.03% | $0 M | Nov 16, 2026 |
| 80 | M&T Bank Corp | 13,781 | New | 0.03% | $0 M | Nov 10, 2026 |
| 81 | Mercer Global Advisors Inc /adv | 13,641 | New | 0.03% | $0 M | Nov 16, 2026 |
| 82 | Invesco Ltd. | 13,388 | +970 (+7.81%) | 0.03% | $0 M | Nov 12, 2026 |
| 83 | Verdad Advisers, LP | 13,300 | New | 0.03% | $0 M | Nov 16, 2026 |
| 84 | Simplex Trading, LLC | 13,194 | New | 0.03% | $0 M | Nov 4, 2026 |
| 85 | Squarepoint Ops LLC | 13,013 | +7,598 (+140.31%) | 0.03% | $0 M | Nov 9, 2026 |
| 86 | Principal Financial Group Inc | 11,267 | New | 0.02% | $0 M | Nov 2, 2026 |
| 87 | Chicago Partners Investment Group LLC | 10,699 | New | 0.02% | $0 M | Oct 27, 2026 |
| 88 | VANGUARD ASSET MANAGEMENT, Ltd | 9,535 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 89 | Legal & General Group Plc | 9,044 | 0 (0.00%) | 0.02% | $0 M | Nov 16, 2026 |
| 90 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 8,960 | -1,622 (-15.33%) | 0.02% | $0 M | Nov 16, 2026 |
| 91 | Virtus Investment Advisers, LLC | 8,834 | -275 (-3.02%) | 0.02% | $0 M | Nov 12, 2026 |
| 92 | China Universal Asset Management Co., Ltd. | 8,249 | +1,063 (+14.79%) | 0.02% | $0 M | Oct 28, 2026 |
| 93 | New York State Common Retirement Fund | 7,700 | -15,886 (-67.35%) | 0.02% | $0 M | Nov 17, 2026 |
| 94 | Nano Cap New Millennium Growth Fund L P | 7,500 | New | 0.02% | $0 M | Nov 13, 2026 |
| 95 | GF Fund Management Co. LTD. | 6,667 | +5,721 (+604.76%) | 0.01% | $0 M | Oct 26, 2026 |
| 96 | Vanguard Global Advisers, LLC | 5,831 | -2,021 (-25.74%) | 0.01% | $0 M | Nov 13, 2026 |
| 97 | Police & Firemen's Retirement System of New Jersey | 5,438 | 0 (0.00%) | 0.01% | $0 M | Nov 9, 2026 |
| 98 | Strs Ohio | 4,900 | +1,400 (+40.00%) | 0.01% | $0 M | Oct 30, 2026 |
| 99 | Arax Advisory Partners | 3,560 | +3,519 (+8582.93%) | 0.01% | $0 M | Nov 12, 2026 |
| 100 | Vanguard Investments Australia, Ltd. | 3,490 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
Superinvestors holding Sionna Therapeutics, Inc.
1 of the well-known investors value.today follows, from their newest Form 13F.
- Viking Global Investors · Andreas Halvorsen$17 M · Sep 30, 2026
Mutual funds holding Sionna Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 934,641 | $41 M | 15.1% | <0.01% | +11% | Jun 30, 2026 |
| 🇺🇸 State Street SPDR S&P Biotech ETFSSGA Funds Management, Inc. | 647,694 | $28 M | 10.5% | 0.27% | +55% | Jun 30, 2026 |
| 🇺🇸 PGIM Jennison Health Sciences FundPGIM INVESTMENTS LLC | 651,048 | $28 M | 10.5% | 2.0% | no change | May 29, 2026 |
| 🇺🇸 JPMorgan Small Cap Growth FundJ.P. Morgan Investment Management Inc. | 524,280 | $23 M | 8.5% | 0.88% | −5.0% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 483,961 | $21 M | 7.8% | 0.03% | +21% | Jun 30, 2026 |
| 🇺🇸 Eventide Healthcare & Life Sciences FundEventide Asset Management, LLC | 474,969 | $21 M | 7.7% | 1.2% | −26% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Health Sciences Fund, Inc.T. Rowe Price Associates, Inc. | 287,643 | $13 M | 4.6% | 0.11% | −47% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 201,838 | $10 M | 3.3% | 0.03% | +26% | Jul 31, 2026 |
| 🇺🇸 abrdn Healthcare Investorsabrdn Inc. | 201,736 | $9 M | 3.3% | 0.65% | −49% | Jun 30, 2026 |
| 🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors | 185,693 | $8 M | 3.0% | 0.09% | +0.3% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 173,168 | $8 M | 2.8% | 0.05% | +31% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 168,369 | $7 M | 2.7% | <0.01% | +5.6% | Jun 30, 2026 |
| 🇺🇸 JPMorgan Small Cap Blend FundJ.P. Morgan Investment Management Inc. | 166,643 | $7 M | 2.7% | 0.43% | −6.5% | Jun 30, 2026 |
| 🇺🇸 Artisan International Small-Mid FundArtisan Partners Limited Partnership | 116,442 | $5 M | 1.9% | 0.20% | new | Jun 30, 2026 |
| 🇺🇸 Franklin Biotechnology Discovery FundFranklin Advisers, Inc. | 107,956 | $5 M | 1.7% | 0.44% | +77% | Jul 31, 2026 |
| 🇺🇸 abrdn Life Sciences Investorsabrdn Inc. | 82,402 | $4 M | 1.3% | 0.53% | −51% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 83,317 | $4 M | 1.3% | 0.02% | +4.7% | May 31, 2026 |
| 🇺🇸 Multi-Manager Small Cap Equity Strategies FundColumbia Funds Series Trust I | 83,093 | $4 M | 1.3% | 0.28% | +1.4% | May 31, 2026 |
| 🇺🇸 Select Biotechnology PortfolioFidelity Management & Research Company LLC | 80,900 | $3 M | 1.3% | 0.07% | new | May 31, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 73,777 | $3 M | 1.2% | <0.01% | −1.8% | May 31, 2026 |
| 🇺🇸 T. Rowe Price New Horizons Fund, Inc.T. Rowe Price Associates, Inc. | 70,768 | $3 M | 1.1% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc. | 69,810 | $3 M | 1.1% | 0.01% | +2.2% | May 31, 2026 |
| 🇺🇸 Vanguard U.S. Momentum Factor ETFThe Vanguard Group, Inc. | 55,058 | $2 M | 0.89% | 0.13% | +46% | May 31, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 44,674 | $2 M | 0.72% | 0.03% | +25% | Jul 31, 2026 |
| 🇺🇸 Driehaus Micro Cap Growth FundDriehaus Capital Management LLC | 46,945 | $2 M | 0.76% | 0.35% | new | Jun 30, 2026 |
| 🇺🇸 ALPS Medical Breakthroughs ETFALPS Advisors, Inc. | 46,379 | $2 M | 0.75% | 1.2% | +17% | May 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 34,469 | $2 M | 0.56% | 0.03% | +27% | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 27,764 | $1 M | 0.45% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 24,424 | $1 M | 0.39% | 0.03% | +26% | Jul 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 26,184 | $1 M | 0.42% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Direxion Daily S&P Biotech Bull 3X SharesRAFFERTY ASSET MANAGEMENT, LLC | 22,009 | $1 M | 0.36% | 0.21% | −7.6% | Jul 31, 2026 |
| 🇺🇸 Adara Smaller Companies FundRBB Fund, Inc. | 22,844 | $1 M | 0.37% | 0.12% | new | May 31, 2026 |
| 🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors | 21,536 | $1 M | 0.35% | <0.01% | +2.6% | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 21,764 | $1 M | 0.35% | <0.01% | +4.9% | May 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 20,147 | $1 M | 0.33% | 0.02% | +17% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Health Sciences PortfolioT. Rowe Price Associates, Inc. | 17,807 | $1 M | 0.29% | 0.10% | −50% | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 17,790 | $1 M | 0.29% | 0.04% | +103% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 17,278 | $1 M | 0.28% | 0.05% | +40% | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 14,944 | $1 M | 0.24% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 15,150 | $1 M | 0.24% | 0.04% | +3.1% | May 31, 2026 |
| 🇺🇸 LVIP Franklin Templeton Multi-Factor SMID Cap Equity FundLincoln Financial Investments Corporation | 14,508 | $1 M | 0.23% | 0.06% | +76% | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 14,099 | $1 M | 0.23% | <0.01% | +17% | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index ETFFidelity Management & Research Company LLC | 13,843 | $1 M | 0.22% | <0.01% | +1.6% | May 31, 2026 |
| 🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC | 12,533 | $1 M | 0.20% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 13,200 | $1 M | 0.21% | 0.03% | +26% | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 8,820 | $0 M | 0.14% | 0.03% | +24% | Jul 31, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 8,762 | $0 M | 0.14% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 9,298 | $0 M | 0.15% | 0.02% | +30% | Jun 30, 2026 |
| 🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC | 8,456 | $0 M | 0.14% | 0.04% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 7,675 | $0 M | 0.12% | <0.01% | +4.2% | Jul 31, 2026 |
| 🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC | 8,167 | $0 M | 0.13% | 0.05% | +1831% | May 31, 2026 |
| 🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc. | 7,386 | $0 M | 0.12% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity MSCI Health Care Index ETFFidelity Management & Research Company LLC | 6,417 | $0 M | 0.10% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 6,575 | $0 M | 0.11% | <0.01% | +49% | Jun 30, 2026 |
| 🇺🇸 Biotechnology Ultrasector ProfundProFund Advisors LLC | 7,374 | $0 M | 0.12% | 0.16% | — | Apr 30, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 6,453 | $0 M | 0.10% | 0.02% | no change | May 31, 2026 |
| 🇺🇸 Health Sciences TrustJohn Hancock Variable Trust Advisers LLC | 6,272 | $0 M | 0.10% | 0.11% | −55% | Jun 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 6,220 | $0 M | 0.10% | 0.03% | +28% | Jun 30, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 6,100 | $0 M | 0.10% | <0.01% | +7.0% | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 5,454 | $0 M | 0.09% | <0.01% | +9.7% | Jul 31, 2026 |
| 🇺🇸 JPMorgan BetaBuilders U.S. Small Cap Equity ETFJ.P. Morgan Investment Management Inc. | 5,243 | $0 M | 0.08% | 0.04% | +14% | Jul 31, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 5,429 | $0 M | 0.09% | 0.02% | +15% | Jun 30, 2026 |
| 🇺🇸 Tax-Managed U.S. Mid & Small Cap FundRussell Investment Management, LLC | 5,014 | $0 M | 0.08% | 0.01% | −65% | Jul 31, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 5,321 | $0 M | 0.09% | 0.03% | +28% | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 5,150 | $0 M | 0.08% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGoldman Sachs Asset Management, L.P. | 5,028 | $0 M | 0.08% | 0.02% | new | May 31, 2026 |
| 🇺🇸 EQ/T.Rowe Price Health Sciences PortfolioEquitable Investment Management Group, LLC | 4,455 | $0 M | 0.07% | 0.11% | −53% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Extended Equity Market Index FundT. Rowe Price Associates, Inc. | 4,438 | $0 M | 0.07% | 0.02% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors | 4,261 | $0 M | 0.07% | <0.01% | −0.8% | Jun 30, 2026 |
| 🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc. | 4,219 | $0 M | 0.07% | 0.05% | new | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 4,121 | $0 M | 0.07% | 0.03% | +30% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 3,798 | $0 M | 0.06% | 0.02% | +28% | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 3,046 | $0 M | 0.05% | 0.02% | +6.2% | Jul 31, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC | 3,064 | $0 M | 0.05% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 2,988 | $0 M | 0.05% | <0.01% | +3731% | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 2,774 | $0 M | 0.04% | <0.01% | +3.2% | Jul 31, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 3,000 | $0 M | 0.05% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 2,896 | $0 M | 0.05% | 0.03% | +27% | Jun 30, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 2,791 | $0 M | 0.05% | 0.03% | +28% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 2,781 | $0 M | 0.04% | 0.03% | +52% | Jun 30, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 2,502 | $0 M | 0.04% | 0.03% | +26% | Jun 30, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 2,238 | $0 M | 0.04% | 0.02% | +3.8% | Jul 31, 2026 |
| 🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC | 2,348 | $0 M | 0.04% | 0.04% | no change | Jun 30, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 2,240 | $0 M | 0.04% | 0.02% | +31% | Jun 30, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 1,984 | $0 M | 0.03% | 0.03% | +8.8% | Jul 31, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 1,637 | $0 M | 0.03% | 0.03% | +27% | Jul 31, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 1,619 | $0 M | 0.03% | <0.01% | +65% | Jul 31, 2026 |
| 🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC | 1,682 | $0 M | 0.03% | 0.05% | +39% | Jun 30, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 1,673 | $0 M | 0.03% | 0.02% | +28% | Jun 30, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 1,468 | $0 M | 0.02% | 0.02% | +44% | Jun 30, 2026 |
| 🇺🇸 Siit Small Cap II FundSEI INVESTMENTS MANAGEMENT CORPORATION | 1,488 | $0 M | 0.02% | 0.03% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 1,360 | $0 M | 0.02% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 1,252 | $0 M | 0.02% | 0.03% | +19% | Jun 30, 2026 |
| 🇺🇸 Siit Small Cap FundSEI INVESTMENTS MANAGEMENT CORPORATION | 1,250 | $0 M | 0.02% | 0.03% | −16% | May 31, 2026 |
| 🇺🇸 SIMT Small Cap FundSEI Institutional Managed Trust | 1,210 | $0 M | 0.02% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Multimanager Aggressive Equity PortfolioEquitable Investment Management Group, LLC | 1,200 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC | 1,174 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC | 1,048 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 iShares Morningstar Small-Cap ETFBlackRock Fund Advisors | 854 | $0 M | 0.01% | 0.01% | +67% | Jul 31, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 822 | $0 M | 0.01% | <0.01% | −28% | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Sionna Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Ra Capital Management, L.P.Director, 10% owner | Sellindirect | -3.42 M | $6.320 | $21.6 M | 3.48 M | Form 4 |
| filed | Ra Capital Management, L.P.Director, 10% owner | Sellindirect | -33,800 | $7.460 | $252 K | 3.45 M | Form 4 |
| filed | Elena RidloffCFO and CBO | Grant or award | +47,269 | — | — | 85,801 | Form 4 |
| filed | Charlotte McKeeCMO and Head of R&D | Grant or award | +50,000 | — | — | 78,415 | Form 4 |
| filed | Michael CloonanPresident & CEO, Director | Grant or award | +109,025 | — | — | 656,368 | Form 4 |
| filed | Jennifer FitzpatrickCLO and Head of Program Mgmt. | Grant or award | +28,133 | — | — | 28,133 | Form 4 |
| filed | Jennifer FitzpatrickCLO and Head of Program Mgmt. | Grant or award | +28,132 | — | — | 56,265 | Form 4 |
| filed | Elena RidloffCFO and CBO | Grant or award | +47,268 | — | — | 133,069 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Sionna Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
IPO: priced at $18.00, raising $190.6M · IPO calendar
Stock splits: 1-for-1.47 reverse split
Fails to deliver
- : 298 shares at $4.04
- : 2,445 shares at $4.91
- : 271 shares at $5.26
- : 1,703 shares at $6.02
- : 1,765 shares at $6.88
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Sionna Therapeutics, Inc. scorecard#
Passes 2 of the 8 checks that could be worked out. Fiscal year 2025; market cap of Oct 29, 2026.
Valuation1 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median0.6×Price to book 0.6× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-36.5%Free cash flow is -36.5% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 1
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-1.88 vs -15.99Diluted EPS -1.88 in fiscal 2025 against -15.99 the year before (report's currency).
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 2
- ✗Profitable in the newest year-$75 MNet income -$75 M in fiscal 2025.
- –Profitable in each of the last five yearsFive years of net income are not on file.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-105.2%-105.2% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 1
- ✓Short-term assets cover short-term liabilities20.6×Current ratio 20.62 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Sionna Therapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 |
|---|---|---|---|
| Income statement | |||
| Research and development | 60+5.2%— | 57—— | |
| General and administrative | 29+116%— | 13—— | |
| Operating expenses | 89+26.1%— | 71—— | |
| Operating income | −89—— | −71—— | |
| Interest and finance income | 13+62.7%— | 8.2—— | |
| Other non-operating income (expense) | 14+54.6%— | 8.9—— | |
| Income tax | 0—— | 0—— | |
| Net income attributable to shareholders | −75—— | −62—— | |
| Earnings per share, basic | -1.88—— | -15.99—— | |
| Earnings per share, diluted | -1.88—— | -15.99—— | |
| Shares, weighted average (basic) | 40+936%— | 3.9—— | |
| Shares, weighted average (diluted) | 40+936%— | 3.9—— | |
| Balance sheet | |||
| Cash and cash equivalents | 58+54.7%17.9% | 38—20.3% | |
| Other current assets | 5.5+60.3%1.7% | 3.5—1.9% | |
| Current assets | 241+59.9%74.1% | 151—81.3% | |
| Property, plant and equipment | 2.2−9.8%0.7% | 2.5—1.3% | |
| Right-of-use (leased) assets | 6.9−11.6%2.1% | 7.8—4.2% | |
| Total assets | 326+75.5%100% | 186—100% | |
| Current liabilities | 12+12.4%3.6% | 10—5.6% | |
| Lease liabilities (non-current) | 7.4−14.6%2.3% | 8.7—4.7% | |
| Total liabilities | 19+0.1%5.9% | 19—10.3% | |
| Retained earnings | −256—−78.6% | −181—−97.5% | |
| Shareholders' equity | 307—94.1% | −164—−88.1% | |
| Total liabilities and equity | 326+75.5%100% | 186—100% | |
| Shares outstanding | 45+847%— | 4.7—— | |
| Cash-flow statement | |||
| Share-based compensation | 12+225%— | 3.7—— | |
| Cash from operating activities | −66—— | −53—— | |
| Capital expenditure | −0.4—— | −0.0—— | |
| Cash from investing activities | −119—— | −127—— | |
| Cash from financing activities | 206+14.9%— | 179—— | |
| Change in cash | 21—— | −0.7—— | |
| Report | 10-K | 10-K | |
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Research and development | 78—— | 22+37.3%— | 22+42.1%— | 19+38.7%— | 15*—— | 16—— | 15—— | 14—— | |
| General and administrative | 42—— | 13+64.8%— | 11+62.6%— | 11+77.5%— | 8.4*—— | 7.8—— | 6.5—— | 6.0—— | |
| Operating expenses | 121—— | 35+46.3%— | 32+48.2%— | 30+50.6%— | 24*—— | 24—— | 22—— | 20—— | |
| Operating income | −121—— | −35—— | −32—— | −30—— | −24*—— | −24—— | −22—— | −20—— | |
| Interest and finance income | 11—— | 2.4−30.4%— | 2.6−29.5%— | 2.8−6.0%— | 3.2*—— | 3.5—— | 3.7—— | 3.0—— | |
| Other non-operating income (expense) | 11—— | 2.4−31.9%— | 2.6−32.7%— | 2.8−11.2%— | 3.2*—— | 3.5—— | 3.8—— | 3.2—— | |
| Net income attributable to shareholders | −110—— | −32—— | −30—— | −27—— | −20*—— | −20—— | −18—— | −16—— | |
| Earnings per share, basic | — | -0.72—— | -0.66—— | -0.60—— | — | -0.46—— | -0.41r-410.00—— | -0.62r-620.00—— | |
| Earnings per share, diluted | — | -0.72—— | -0.66—— | -0.60—— | — | -0.46—— | -0.41r-410.00—— | -0.62r-620.00—— | |
| Shares, weighted average (basic) | 45—— | 45+2.2%— | 45+2.3%— | 45+68.9%— | — | 44—— | 44—— | 27—— | |
| Shares, weighted average (diluted) | 45—— | 45+2.2%— | 45+2.3%— | 45+68.9%— | — | 44—— | 44—— | 27—— | |
| Balance sheet | |||||||||
| Cash and cash equivalents | 84—31.9% | 84+65.0%31.9% | 63+54.5%22.4% | 63−23.4%20.8% | 58—17.9% | 51—15.0% | 41—11.6% | 83—22.4% | |
| Other current assets | 3.9—1.5% | 3.9−1.5%1.5% | 5.1+22.1%1.8% | 4.8+19.8%1.6% | 5.5—1.7% | 4.0—1.2% | 4.2—1.2% | 4.0—1.1% | |
| Current assets | 229—86.8% | 229−9.4%86.8% | 216−19.0%76.3% | 221−19.3%72.4% | 241—74.1% | 252—74.4% | 267—75.8% | 274—74.0% | |
| Property, plant and equipment | 1.8—0.7% | 1.8−17.8%0.7% | 1.9−14.7%0.7% | 2.1−13.5%0.7% | 2.2—0.7% | 2.1—0.6% | 2.2—0.6% | 2.4—0.6% | |
| Right-of-use (leased) assets | 6.2—2.3% | 6.2−14.0%2.3% | 6.4−13.1%2.3% | 6.7−12.3%2.2% | 6.9—2.1% | 7.2—2.1% | 7.4—2.1% | 7.6—2.1% | |
| Total assets | 263—100% | 263−22.4%100% | 283−19.5%100% | 305−17.5%100% | 326—100% | 339—100% | 352—100% | 370—100% | |
| Current liabilities | 16—6.2% | 16+66.7%6.2% | 11+42.8%3.8% | 9.8+2.6%3.2% | 12—3.6% | 9.9—2.9% | 7.6—2.1% | 9.5—2.6% | |
| Lease liabilities (non-current) | 6.3—2.4% | 6.3−18.5%2.4% | 6.7−17.1%2.4% | 7.1−15.8%2.3% | 7.4—2.3% | 7.8—2.3% | 8.1—2.3% | 8.4—2.3% | |
| Total liabilities | 23—8.6% | 23+29.2%8.6% | 17+11.9%6.2% | 17−6.0%5.5% | 19—5.9% | 18—5.2% | 16—4.4% | 18—4.8% | |
| Retained earnings | −345—−131% | −345—−131% | −313—−111% | −283—−92.8% | −256—−78.6% | −236—−69.5% | −216—−61.3% | −198—−53.4% | |
| Shareholders' equity | 241—91.4% | 241−25.2%91.4% | 266−21.0%93.8% | 288−18.1%94.5% | 307—94.1% | 322—94.8% | 336—95.6% | 352—95.2% | |
| Total liabilities and equity | 263—100% | 263−22.4%100% | 283−19.5%100% | 305−17.5%100% | 326—100% | 339—100% | 352—100% | 370—100% | |
| Shares outstanding | 45—— | 45+1.7%— | 45+2.3%— | 45+2.2%— | 45—— | 44—— | 44—— | 44—— | |
| Cash-flow statement | |||||||||
| Share-based compensation | 24—— | 7.1+114%— | 6.8+141%— | 6.6+213%— | 3.8*—— | 3.3—— | 2.8—— | 2.1—— | |
| Cash from operating activities | −79—— | −19*—— | −22*—— | −22—— | −17*—— | −15*—— | −18*—— | −16—— | |
| Capital expenditure | −0.2—— | 0*—— | 0*—— | 0—— | −0.2*—— | −0.1*—— | 0*—— | −0.1—— | |
| Cash from investing activities | 108—— | 39*+68.6%— | 21*—— | 25—— | 23*—— | 23*—— | −23*—— | −141—— | |
| Cash from financing activities | 4.6—— | 0.3*−83.1%— | 0.7*—— | 1.9−99.1%— | 1.7*—— | 2.0*—— | −0.3*—— | 202—— | |
| Change in cash | 33—— | 21*+109%— | −0.0*—— | 4.9−89.1%— | 7.6*—— | 9.8*—— | −42*—— | 45—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Sionna Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Restructuring 1 · Directors and officers 1 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 8
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| RestructuringDirectors and officers | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Bylaws or fiscal year changed | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 46% of workforce | Restructuring planSEC 8-K | “The Restructuring includes a reduction of the Company’s workforce by approximately 46%, retaining core clinical, regulatory, technical, and corporate capabilities required to advan…” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Sionna Therapeutics, Inc. compares in Biotechnology
- Market cap$183 M · higher than 43% of 726
- Price / book0.6× · lower than 89% of 534
- FCF yield-36.5% · higher than 30% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Sionna Therapeutics, Inc.🇺🇸 | $183 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 29, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of February 15, 2026
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Sionna Therapeutics, Inc.? Verify and update this profile — free
Show Sionna Therapeutics, Inc.'s ranking on your website Get the badge
The badge updates itself as the ranking changes.